Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke.

AIMS Recurrent stroke is a frequent and disabling event. A high heart rate is associated with cardiovascular outcomes. We investigated the effects of the resting heart rate on cardiovascular and neurological outcomes after recurrent stroke in the high-risk population of the PRoFESS study. METHODS AND RESULTS A total of 20,165 patients after ischaemic stroke (mean age 66.1, SD 8.6 years) assigned to the treatment arms of the PRoFESS trial were pooled divided by quintiles of the baseline heart rate and analysed according to cardiovascular and functional outcomes after stroke: recurrent stroke and major cardiovascular outcomes such as stroke, myocardial infarction, and worsening or new-onset heart failure as well as death from cardiovascular and non-cardiovascular causes. Pre-defined endpoints were disability after a recurrent stroke, assessed with the modified Rankin scale (mRS) and the Barthel index at 3 months, and cognitive function, assessed with the Mini-Mental State Examination (MMSE) score at 4 weeks after randomization and at the penultimate visit. Patients in the two highest quintiles of heart rate (77-82 and >82 b.p.m.) were at a higher risk for total death [hazard ratio (HR) 1.42, 95% CI 1.19-1.69 and HR 1.74, 95% CI 1.48-2.06, P < 0.0001] compared with the lowest quintile. Similar results were observed for vascular death [71-≤76 b.p.m., HR 1.39 (1.11-1.74), P < 0.0001] and non-vascular death [from >82 b.p.m., HR 1.66 (1.29-2.13), P = 0.0016]. Myocardial infarction (P = 0.7084) and recurrent stroke (P = 0.1379) were not significantly associated with the baseline heart rate. Hazard ratios were adjusted to multiple confounders including the baseline blood pressure. In the group of patients with a recurrent stroke, an association of a lower heart rate to better outcomes was measured with the Barthel index across all heart rate groups. In addition, there was a significant association of the baseline heart rate to the occurrence of significant cognitive decline according to an MMSE score ≤24 points at 1 month and at the penultimate visit or a decline of ≥2 points between these two time periods. Better independence score at a low heart rate were observed. CONCLUSION The heart rate is a risk indicator for mortality in patients with stroke and, importantly, a low heart rate is associated with a better functional outcome and less cognitive decline after an ischaemic stroke. TRIAL REGISTRATION ClinicalTrials.gov, number NTC00153062.

[1]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[2]  U. Laufs,et al.  Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. , 2012, European heart journal.

[3]  P. Okin,et al.  Effect of changing heart rate during treatment of hypertension on incidence of heart failure. , 2012, The American journal of cardiology.

[4]  G. Mancia,et al.  Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. , 2012, The American journal of cardiology.

[5]  W. Elliott Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke , 2012 .

[6]  Javaid Nauman,et al.  Temporal changes in resting heart rate and deaths from ischemic heart disease. , 2011, JAMA.

[7]  Salim Yusuf,et al.  Level of systolic blood pressure within the normal range and risk of recurrent stroke. , 2011, JAMA.

[8]  M. Endres,et al.  Stress Worsens Endothelial Function and Ischemic Stroke via Glucocorticoids , 2011, Stroke.

[9]  MichaelBöhm,et al.  Heart Rate Contributes to the Vascular Effects of Chronic Mental Stress , 2011 .

[10]  M. Gold,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2011 .

[11]  M. Cheitlin Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2011 .

[12]  Irene Katzan,et al.  Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. , 2011, Stroke.

[13]  U. Laufs,et al.  Vascular pathophysiology in response to increased heart rate. , 2010, Journal of the American College of Cardiology.

[14]  Michael Böhm,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.

[15]  U. Laufs,et al.  Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. , 2010, Atherosclerosis.

[16]  Richard B Devereux,et al.  All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. , 2010, European heart journal.

[17]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[18]  Michael Böhm,et al.  Heart rate reduction in cardiovascular disease and therapy , 2010, Clinical Research in Cardiology.

[19]  W. Elliott Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events , 2009 .

[20]  A. Rabinstein Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke , 2009 .

[21]  S. Yusuf,et al.  Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo , 2008, The Lancet Neurology.

[22]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[23]  U. Laufs,et al.  Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E–Deficient Mice , 2008, Circulation.

[24]  C. Pepine,et al.  Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.

[25]  M. Nieminen,et al.  Abstract 2293: Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study , 2006 .

[26]  Jean-Claude Tardif,et al.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.

[27]  M. Caldwell,et al.  American Heart Association: Council on Cardiovascular Nursing , 2004, The Journal of cardiovascular nursing.

[28]  ParveenRashid,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events , 2003 .

[29]  J. Leonardi-Bee,et al.  Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review , 2003, Stroke.

[30]  U. Heidland,et al.  Left Ventricular Muscle Mass and Elevated Heart Rate Are Associated With Coronary Plaque Disruption , 2001, Circulation.

[31]  H. Levine Rest heart rate and life expectancy. , 1997, Journal of the American College of Cardiology.

[32]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.

[33]  A. Coburn,et al.  Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. , 1974, The Johns Hopkins medical journal.

[34]  T. Cottle The Life Study , 1973 .

[35]  Coburn Af,et al.  Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. , 1971 .